GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Price-to-Operating-Cash-Flow

Durect (Durect) Price-to-Operating-Cash-Flow : (As of Apr. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Durect Price-to-Operating-Cash-Flow?

As of today (2024-04-28), Durect's share price is $0.9313. Durect's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.32. Hence, Durect's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Durect's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Durect's highest Price-to-Operating-Cash-Flow Ratio was 224.04. The lowest was 25.37. And the median was 150.00.

DRRX's Price-to-Operating-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.14
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Durect's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.28. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.32.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 12.50% per year.

During the past 13 years, Durect's highest 3-Year average Operating Cash Flow per Share Growth Rate was 58.70% per year. The lowest was -176.30% per year. And the median was 4.55% per year.


Durect Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Durect's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Price-to-Operating-Cash-Flow Chart

Durect Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.90 - - - -

Durect Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Durect's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durect's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Durect's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Durect's Price-to-Operating-Cash-Flow falls into.



Durect Price-to-Operating-Cash-Flow Calculation

Durect's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=0.9313/-1.32
=

Durect's Share Price of today is $0.9313.
Durect's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Durect Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Durect's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (Durect) Business Description

Industry
Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Executives
Judith J. Robertson director 10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis director 364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp officer: Chief Financial Officer C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia director ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman officer: Chief Medical Officer C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice officer: Sr. VP Operations & Corp QA 10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg officer: Chief Financial Officer 10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown director, officer: President & CEO 10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105